Trial | % Cholesterol reduction in trial | % Decrease in new CHD per 1% cholesterol reduction | |
---|---|---|---|
*Primary prevention trials. | |||
Cholesterol (total-LDL) lowering treatment | |||
Bile acid sequestrant | *LRCCw44 | −11 | 2.2 |
HMG Co-A reductase inhibitors (statins) | *WOSCOPSw45 | −20 | 1.6 |
*AFCAPS/TexCAPSw46 | −18 | 2.1 | |
4Sw10 | −29 | 1.1 | |
CAREw11 | −20 | 1.2 | |
LIPID w12 | −18 | 1.3 | |
Triglyceride lowering treatment | |||
Fibrate | *WHOw47 | −9 | 2.2 |
*Helsinki Heart Studyw48 | −10 | 3.4 | |
Scandinavian Secondary Prevention Studyw34 | −13 | 3.2 | |
*SENDCAPw49 | −7 | 9.7 | |
VA-HITw35 | −4 | 5.5 |